Immutep Limited (ASX:IMM) Reports Q3 FY25 Milestones and Financial Position
Clinical Trial Milestones
Immutep Limited successfully dosed the first patient in its pivotal TACTI-004 Phase III lung cancer trial. The TACTI-004 trial, evaluating eftilagimod alfa (efti) in combination with KEYTRUDA® and chemotherapy, aims to treat advanced non-small cell lung cancer (1L NSCLC) across approximately 756 patients globally. Additionally, Immutep completed patient enrolment for the EFTISARC-NEO Phase II trial and the INSIGHT-003 Phase I trial, both evaluating efti in combination with KEYTRUDA® for different cancer types.
Financial Position
The company reported a strong cash position of A$146.25 million as of 31 March 2025, ensuring financial stability through the end of calendar year 2026. Cash inflows from investing activities amounted to $32.34 million, primarily from the maturity of short-term investments, while net cash used in operating activities was $16.26 million for the quarter.
Intellectual Property
Immutep secured two new patents for LAG525 in the Philippines and the United States. Additionally, a Russian patent was granted for an assay used in measuring the potency of IMP761, enhancing the company’s intellectual property portfolio.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
